Take Solutions shares surged 5% to ₹27.98 after reporting a significant turnaround in profitability during the March quarter. According to reports from LiveMint, the company posted a consolidated net profit of ₹4.36 crore for Q4 FY26, compared with a net loss of ₹4.88 crore recorded during the corresponding quarter of the previous financial year. The stock witnessed strong buying interest following this operational improvement, with the company also reporting revenue of ₹54.19 crore during the March quarter of FY26, compared with no revenue reported during the same quarter last year.
Despite the quarterly turnaround, the company's full-year profitability declined sharply on a year-on-year basis. As reported by LiveMint, net profit fell 71.04% to ₹10.85 crore for FY26, compared with ₹37.47 crore reported during FY25. However, the company achieved annual revenue of ₹54.19 crore for the financial year ended March 2026, while no revenue had been reported during the previous financial year. The earnings performance marked a significant operational improvement for the company focusing on expanding its presence across healthcare technology, artificial intelligence and digital health solutions.
During FY26, Take Solutions continued strengthening its focus on AI-led healthcare solutions and innovation-driven businesses. According to LiveMint, as part of this strategy, the company launched a ₹5 crore Innovation Fund aimed at supporting startups operating in artificial intelligence, deep technology and digital healthcare segments. The company also expanded its presence in the health and wellness space through its AI-driven platform, Take.Health, which remains a key part of its long-term digital healthcare strategy. Management indicated that the company remains focused on building an innovation-led ecosystem while strengthening capabilities in healthcare technology solutions.
The stock has been in the red recently, down 43% in 1 month and 40% in 3 months, as reported by LiveMint. However, it has given multibagger returns in the last 1 year, rising 180%. The scrip has been trading between its 52-week high of ₹49.90 in February 2026 and its 52-week low of ₹8.16 in June 2025. Commenting on the company's performance, Parmeshvar Dhangare, Director of Take Solutions Limited, stated that FY26 marked an important phase for strengthening the company's position across healthcare technology and digital solutions businesses.
